{
    "clinical_study": {
        "@rank": "132724", 
        "acronym": "DNKI-II", 
        "brief_summary": {
            "textblock": "The protocol treatment is to evaluate clinical effects of donor-derived natural killer cells\n      that are given after HLA-mismatched hematopoietic cell transplantation."
        }, 
        "brief_title": "Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Acute Lymphoblastic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Those patients with acute leukemia, which is not responding to coventional chemotherapy,\n      will be treated. The clinical effects will be evaulated in terms of safety (side effects)\n      and anti-leukemia effect."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with acute leukemia, which are refractory to standard treatment. Patients should\n        be 17 years of age or older. The performance status of the patients should be 70 or over\n        by Karnofsky scale. Patients should not have excessive hepatic dysfunction (bilirubin less\n        than 3.0 mg/dl, AST less than 5 times the upper normal limit).\n\n        Patients should not have excessive renal dysfunction (creatinine less than 3.0 mg/dl).\n\n        Patients should not have clinically-evident cardiac or pulmonary dysfunction. Patients and\n        donors must sign informed consent.\n\n        Exclusion Criteria:\n\n        Patients who are pregnant or lactating are not eligible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "85", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795378", 
            "org_study_id": "AMC 2012-0478"
        }, 
        "intervention": {
            "description": "Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.\nThe patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).\nFor DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.\nThe dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg.", 
            "intervention_name": "donor natural killer cell infusion", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute myelogenous leukemia", 
            "acute lymphoblastic leukemia", 
            "donor natural killer cells", 
            "HLA-haploidentical hematopoietic cell transplantation"
        ], 
        "lastchanged_date": "February 19, 2013", 
        "location": {
            "contact": {
                "email": "khlee2@amc.seoul.kr", 
                "last_name": "Kyoo-Hyung Lee, M.D.", 
                "phone": "82-2-3010-3210"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyoo-Hyung Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY", 
        "overall_contact": {
            "email": "khlee2@amc.seoul.kr", 
            "last_name": "Kyoo-Hyung Lee, M.D.", 
            "phone": "82-2-3010-3213"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "occurrence and severity of side effects of donor natural killer cell infusion", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "reference": [
            {
                "PMID": "21715313", 
                "citation": "Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28."
            }, 
            {
                "PMID": "19881555", 
                "citation": "Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, Kim DY, Kang YA, Jeon M, Seol M, Ryu SG, Chung JW, Choi I, Lee KH. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010 Jun;45(6):1038-46. doi: 10.1038/bmt.2009.304. Epub 2009 Nov 2."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795378"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Kyoo-Hyung Lee", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "anti-leukemia effect of donor natural killer cell infusion", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Korea Research Institute of Bioscience and Biotechnology", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}